Evidence map›Paper›PMID 35192139›Full record

ReviewCurrent treatment options in oncology2022

Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.

Morgan Pugh-Toole, Anna P Nicolela, Sarah Nersesian, Brendan M Leung, Jeanette E Boudreau

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Morgan Pugh-TooleDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Anna P NicolelaDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Sarah NersesianBeatrice Hunter Cancer Research Institute, Halifax, Nova Scotia, Canada.
Brendan M LeungDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
Jeanette E BoudreauDepartment of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada. Jeanette.boudreau@dal.ca.ORCID http://orcid.org/0000-0003-0203-2180
Dalhousie University · CAQueen's University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementOvarian cancer (OC), especially high-grade serous cancer (HGSC), is a highly heterogeneous malignancy with limited options for curative treatment and a high frequency of relapse. Interactions between OC and the immune system may permit immunoediting and immune escape, and current standard of care therapies can influence immune cell infiltration and function within the tumor microenvironment. Natural killer (NK) cells are involved in cancer immunosurveillance and immunoediting and can be activated by therapy, but deliberate approaches to maximize NK cell reactivity for treatment of HGSC are in their infancy. NK cells may be the ideal target for immunotherapy of HGSC. The diverse functions of NK cells, and their established roles in immunosurveillance, make them attractive candidates for more precise and effective HGSC treatment. NK cells' functional capabilities differ because of variation in receptor expression and genetics, with meaningful impacts on their anticancer activity. Studying HGSC:NK cell interactions will define the features that predict the best outcomes for patients with the disease, but the highly diverse nature of HGSC will likely require combination therapies or approaches to simultaneously target multiple, co-existing features of the tumor to avoid tumor escape and relapse. We expect that the ideal therapy will enable NK cell infiltration and activity, reverse immunosuppression within the tumor microenvironment, and enable effector functions against the diverse subpopulations that comprise HGSC.

Indexed as

Neoplasm Recurrence, LocalOvarian NeoplasmsCarcinoma, Ovarian EpithelialFemaleHumansKiller Cells, NaturalTumor MicroenvironmentCombination therapyHigh-grade serous carcinomaImmunotherapyNatural killer cellsOvarian cancer

Identifiers

PMID35192139
OpenAlexW4212810560

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.